Alexander J Butwick1, Lawrence T Goodnough. 1. aDepartment of Anesthesiology bDepartment of Pathology cDepartment of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Abstract
PURPOSE OF REVIEW: Major obstetric hemorrhage is a leading cause of maternal morbidity and mortality. We will review transfusion strategies and the value of monitoring the maternal coagulation profile during severe obstetric hemorrhage. RECENT FINDINGS: Epidemiologic studies indicate that rates of severe postpartum hemorrhage (PPH) in well resourced countries are increasing. Despite these increases, rates of transfusion in obstetrics are low (0.9-2.3%), and investigators have questioned whether a predelivery 'type and screen' is cost-effective for all obstetric patients. Instead, blood ordering protocols specific to obstetric patients can reduce unnecessary antibody testing. When severe PPH occurs, a massive transfusion protocol has attracted interest as a key therapeutic resource by ensuring sustained availability of blood products to the labor and delivery unit. During early postpartum bleeding, recent studies have shown that hypofibrinogenemia is an important predictor for the later development of severe PPH. Point-of-care technologies, such as thromboelastography and rotational thromboelastometry, can identify decreased fibrin clot quality during PPH, which correlate with low fibrinogen levels. SUMMARY: A massive transfusion protocol provides a key resource in the management of severe PPH. However, future studies are needed to assess whether formula-driven vs. goal-directed transfusion therapy improves maternal outcomes in women with severe PPH.
PURPOSE OF REVIEW: Major obstetric hemorrhage is a leading cause of maternal morbidity and mortality. We will review transfusion strategies and the value of monitoring the maternal coagulation profile during severe obstetric hemorrhage. RECENT FINDINGS: Epidemiologic studies indicate that rates of severe postpartum hemorrhage (PPH) in well resourced countries are increasing. Despite these increases, rates of transfusion in obstetrics are low (0.9-2.3%), and investigators have questioned whether a predelivery 'type and screen' is cost-effective for all obstetric patients. Instead, blood ordering protocols specific to obstetric patients can reduce unnecessary antibody testing. When severe PPH occurs, a massive transfusion protocol has attracted interest as a key therapeutic resource by ensuring sustained availability of blood products to the labor and delivery unit. During early postpartum bleeding, recent studies have shown that hypofibrinogenemia is an important predictor for the later development of severe PPH. Point-of-care technologies, such as thromboelastography and rotational thromboelastometry, can identify decreased fibrin clot quality during PPH, which correlate with low fibrinogen levels. SUMMARY: A massive transfusion protocol provides a key resource in the management of severe PPH. However, future studies are needed to assess whether formula-driven vs. goal-directed transfusion therapy improves maternal outcomes in women with severe PPH.
Authors: M D Lancé; M Ninivaggi; S E M Schols; M A H Feijge; S K Oehrl; G J A J M Kuiper; M Nikiforou; M A E Marcus; K Hamulyak; E C M van Pampus; H ten Cate; J W M Heemskerk Journal: Vox Sang Date: 2011-12-28 Impact factor: 2.144
Authors: Ove Karlsson; Tommy Sporrong; Andreas Hillarp; Anders Jeppsson; Margareta Hellgren Journal: Anesth Analg Date: 2012-07-19 Impact factor: 5.108
Authors: S Ahmed; C Harrity; S Johnson; S Varadkar; S McMorrow; R Fanning; C M Flynn; J M O' Riordan; B M Byrne Journal: Transfus Med Date: 2012-10 Impact factor: 2.019
Authors: L de Lloyd; R Bovington; A Kaye; R E Collis; R Rayment; J Sanders; A Rees; P W Collins Journal: Int J Obstet Anesth Date: 2011-04 Impact factor: 2.603
Authors: Roch Cantwell; Thomas Clutton-Brock; Griselda Cooper; Andrew Dawson; James Drife; Debbie Garrod; Ann Harper; Diana Hulbert; Sebastian Lucas; John McClure; Harry Millward-Sadler; James Neilson; Catherine Nelson-Piercy; Jane Norman; Colm O'Herlihy; Margaret Oates; Judy Shakespeare; Michael de Swiet; Catherine Williamson; Valerie Beale; Marian Knight; Christopher Lennox; Alison Miller; Dharmishta Parmar; Jane Rogers; Anna Springett Journal: BJOG Date: 2011-03 Impact factor: 6.531
Authors: Natascha M de Lange; Marcus D Lancé; Reneé de Groot; Erik A M Beckers; Yvonne M Henskens; Hubertina C J Scheepers Journal: Obstet Gynecol Surv Date: 2012-07 Impact factor: 2.347
Authors: K Seligman; B Ramachandran; P Hegde; E T Riley; Y Y El-Sayed; L M Nelson; A J Butwick Journal: Int J Obstet Anesth Date: 2017-03-22 Impact factor: 2.603
Authors: Lucia Stanciakova; Miroslava Dobrotova; Pavol Holly; Jana Zolkova; Lubica Vadelova; Ingrid Skornova; Jela Ivankova; Tomas Bolek; Matej Samos; Marian Grendar; Jan Danko; Peter Kubisz; Jan Stasko Journal: Diagnostics (Basel) Date: 2021-05-03